Abstract

Objectives: We sought to determine the impact of stroke and major bleeding excluding intracranial hemorrhage (MB) events on healthcare costs in a real-world nonvalvular atrial fibrillation (NVAF) population. Methods: Healthcare claims data from U.S. commercial and Medicare health plans were used to identify beneficiaries with NVAF during 2008-2012. Patients were classified into cohorts according to event type (No event, Stroke only, MB only, or Stroke plus MB). All-cause total healthcare costs and inpatient costs related to stroke and MB were calculated during 1-year period following the index date (date of initial event or first qualifying AF claim for No event group). Inpatient hospitalizations related to events were identified using ICD-9-CM diagnosis codes. Costs were standardized to 2012 US dollars. Results: Of the 40,654 patients included in the study, 28% had events (8.9% Stroke only, 14.5% MB only, and 4.7% Stroke plus MB). Relative to the No event cohort, all-cause unadjusted per-patient per-month (PPPM) total costs were $4,669 higher for Stroke only and $4,160 for MB only. For Stroke plus MB patients, unadjusted all-cause PPPM total costs were $6,322 higher compared to the No event cohort. Among Stroke only and MB only patients, the economic burden of hospitalizations related to MB (57% of total costs) was similar to Stroke only (63% of total costs). Hospitalizations related to stroke or MB accounted for 65% of total costs for Stroke plus MB. Conclusions: NVAF patients who have a stroke or MB event incur higher healthcare costs relative to patients without events. Interventions preventing stroke or MB events have the potential to reduce the healthcare burden associated NVAF.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call